Case Summary:  

We are pleased to share the successful approval of an EB-2 NIW (National Interest Waiver) petition for a resident in the field of radiology and imaging sciences from India. Our expert team meticulously crafted a compelling petition for this client who holds an M.B.B.S. degree.

Despite receiving a Request for Evidence (RFE), our firm promptly prepared a comprehensive response highlighting the objective metrics and real-world impact on patient health outcomes. Following our thorough RFE response, the client’s NIW petition was approved after 6 months under premium processing.

Key Research Contributions:

As an expert in radiology and imaging sciences, the client’s proposed endeavor is to continue research investigating diagnostic and therapeutic radiopharmaceuticals through molecular imaging techniques and targeted radionuclide therapies to enhance their clinical utility for managing cancers, cardiovascular diseases, neurodegenerative conditions, and other systemic illnesses.

We demonstrated that the client’s research has far-reaching implications for the United States, advancing radiopharmaceutical technologies when the nation faces a projected 2 million new cancer cases annually. The work enhances diagnostic precision, enables timely intervention, and supports personalized treatment approaches that strengthen healthcare infrastructure nationwide.

To further strengthen the case, we highlighted the client’s impressive credentials:

• 14 peer-reviewed journal articles (6 first-authored) and 6 abstracts (1 first-authored)
• Research cited 59 times according to Google Scholar
• At least 3 papers ranking among the top 1%, top 10%, and top 20% most cited articles in the field
• Completed at least 6 peer reviews for prestigious journals
• Competitive funding from the National Cancer Institute of the National Institutes of Health

The petition included 2 strong recommendation letters, including 1 independent advisory opinion from an expert who emphasized how the work provides a foundation for continued progress in nuclear medicine and molecular imaging.

“Considering the value presented by continued innovation via the discovery of novel applications of radiopharmaceuticals in diagnostic and therapeutic approaches, halting [The Client]’s research would be damaging to nuclear medicine and molecular imaging research by slowing the progression of this critical area. It is, therefore, within the interests of the United States to allow [The Client]’s research to continue. “

Result:

USCIS recognized that the client’s sustained record of excellence and nationally important contributions position them well to continue advancing radiopharmaceutical innovations that strengthen U.S. healthcare infrastructure and benefit patients across the nation. We are honored to have supported this exceptional physician-scientist and extend our sincere best wishes for continued success in advancing medical imaging research and improving patient care.